Abstract
Metallodrugs (organometallic complexes) bearing at least one metal-carbon bond - represent original and powerful tools for diverse therapeutic applications based on the development of “bioorganometallic chemistry”. To date, various metallodrugs were described with very interesting biological activities as antimalarials, antibacterials, neuroprotectors, against arthritis, for chemotherapy etc. Anticancer Pt-based drugs are the main complexes used in the treatment of several cancers, but unfortunately these complexes show elicit and severe toxicities and resistance effects. The remarkably unique and tunable properties of dendrimers have made them promising tools for diverse biomedical applications such as diagnostics, gene therapy and drug delivery including in oncology. Recent studies have shown that well designed dendritic carriers overcome such as poor solubility, permeability, biocompatibility, bioavailability and toxicity of the native drug. This review reports on the recent advances for the use of metallodrugs and dendritic based carriers (drug-dendrimer conjugates and drug encapsulation) in oncology. Advantages, limitations and opportunities in oncology of such materials are discussed and compared.
Keywords: Metal complexes, dendrimers, drugs, nanotheraphy, oncology
Current Medicinal Chemistry
Title:From Metallodrugs to Metallodendrimers for Nanotherapy in Oncology: A Concise Overview
Volume: 19 Issue: 29
Author(s): S. El Kazzouli, N. El Brahmi, S. Mignani, M. Bousmina, M. Zablocka and J. -P. Majoral
Affiliation:
Keywords: Metal complexes, dendrimers, drugs, nanotheraphy, oncology
Abstract: Metallodrugs (organometallic complexes) bearing at least one metal-carbon bond - represent original and powerful tools for diverse therapeutic applications based on the development of “bioorganometallic chemistry”. To date, various metallodrugs were described with very interesting biological activities as antimalarials, antibacterials, neuroprotectors, against arthritis, for chemotherapy etc. Anticancer Pt-based drugs are the main complexes used in the treatment of several cancers, but unfortunately these complexes show elicit and severe toxicities and resistance effects. The remarkably unique and tunable properties of dendrimers have made them promising tools for diverse biomedical applications such as diagnostics, gene therapy and drug delivery including in oncology. Recent studies have shown that well designed dendritic carriers overcome such as poor solubility, permeability, biocompatibility, bioavailability and toxicity of the native drug. This review reports on the recent advances for the use of metallodrugs and dendritic based carriers (drug-dendrimer conjugates and drug encapsulation) in oncology. Advantages, limitations and opportunities in oncology of such materials are discussed and compared.
Export Options
About this article
Cite this article as:
El Kazzouli S., El Brahmi N., Mignani S., Bousmina M., Zablocka M. and -P. Majoral J., From Metallodrugs to Metallodendrimers for Nanotherapy in Oncology: A Concise Overview, Current Medicinal Chemistry 2012; 19 (29) . https://dx.doi.org/10.2174/0929867311209024995
DOI https://dx.doi.org/10.2174/0929867311209024995 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MRI findings and renal function in patients on lithium therapy
Current Drug Safety Subject Index to Volume 5
Current Drug Targets Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks
Current Medicinal Chemistry G-Protein Signaling, Lipid Rafts and the Possible Sites of Action for the Antidepressant Effects of n-3 Polyunsaturated Fatty Acids
CNS & Neurological Disorders - Drug Targets The Potential Effect of Carvedilol Against Osteoporosis in Ovariectomized Rats
Current Drug Therapy Osteoporosis and its Association with Non-Gonadal Hormones Involved in Hypertension, Adiposity and Hyperglycaemia
Current Drug Targets Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice
Letters in Drug Design & Discovery Recent Progress in BINOL Mediated Asymmetric Reactions
Mini-Reviews in Organic Chemistry Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Cellular Mechanisms that Edit the Immunopeptidome
Current Proteomics Anti-inflammatory Augmentation Therapy in Obsessive-compulsive Disorder: A Review
Letters in Drug Design & Discovery Synthesis of Novel Heterocyclic Prostaglandin Analogues
Letters in Organic Chemistry Protein Tyrosine Phosphatase SHP-2 as Drug Target
Mini-Reviews in Organic Chemistry Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Cystatin F Regulates Proteinase Activity in IL-2-activated Natural Killer Cells
Protein & Peptide Letters Herbals and Natural Dietary Supplements in Psychiatric Practice
Recent Patents on CNS Drug Discovery (Discontinued) Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Editorial: [Cytokines as Anti-Cancer Agents Rational, Results and Perspectives (Guest Editor: S. Mocellin)]
Current Medicinal Chemistry